Loading...
•
Dec 31, 2025
EyePoint Pharmaceuticals Q4 2025 Earnings Report
EyePoint Pharmaceuticals Q4 2025 Earnings Report
Key Takeaways
EyePoint Pharmaceuticals reported a significant decrease in revenue for Q4 2025, primarily due to the exhaustion of deferred revenue from a 2023 licensing agreement. The company is heavily investing in Phase 3 clinical trials for DURAVYU in wet AMD and DME, leading to increased operating losses, but maintains a strong cash position of over $300 million to fund operations into late 2027.
Pivotal Phase 3 trials (LUGANO and LUCIA) for DURAVYU in wet AMD are on track for topline data readouts beginning in mid-2026.
First patients have been dosed in the Phase 3 COMO and CAPRI clinical trials for DURAVYU in Diabetic Macular Edema (DME).
Total net revenue dropped to $0.6 million from $11.6 million year-over-year as YUTIQ license deferred revenue was fully recognized in prior periods.
Cash runway is extended into Q4 2027 following a $172.5 million public offering completed in October 2025.
Revenue by Segment
Forward Guidance
EyePoint expects its current cash and investments to fund operations into the fourth quarter of 2027, covering major Phase 3 milestones.
Positive Outlook
- Cash runway extends into Q4 2027.
- LUGANO Phase 3 topline data expected in mid-2026.
- LUCIA Phase 3 topline data expected shortly after LUGANO.
- DME Phase 3 topline data expected in the second half of 2027.
- Manufacturing of registration batches for DURAVYU is complete.
Challenges Ahead
- Significant ongoing operating losses due to high R&D spend.
- Revenue from legacy products and licenses has decreased significantly.
- FDA approval and the timeline for potential approval remains uncertain.
- Dependence on successful clinical outcomes for a single primary candidate (DURAVYU).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...